[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.107.222. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 299
Citations 0
Correspondence
Nov 2012

Interleukin 12/23 Agents and Major Adverse Cardiovascular Events

Author Affiliations

Author Affiliation: Department of Dermatology, Mount Sinai School of Medicine, New York, New York.

Arch Dermatol. 2012;148(11):1329. doi:10.1001/2013.jamadermatol.88

The JAMA article by Ryan et al1 on the association between biological therapies for psoriasis and cardiovascular events and the commentary by Bigby2 have generated significant controversy in the community of psoriasis researchers. By drawing attention to a potential increase in cardiovascular events in patients treated with interleukin (IL)-12/23 antagonists, the article and commentary provide a service to dermatologists and our patients.

First Page Preview View Large
First page PDF preview
First page PDF preview
×